Literature DB >> 15083604

SB-480848. GlaxoSmithKline.

David P Rotella1.   

Abstract

SB-480848 is a reversible lipoprotein-associated phospholipase A2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15083604

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Cloning, expression, and purification of lipoprotein-associated phospholipase A(2) in Pichia pastoris.

Authors:  Fujun Zhang; Yiping Wang
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

Review 2.  Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

Authors:  Vijay Nambi; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

3.  Increased phospholipase A2 and lyso-phosphatidylcholine levels are associated with surfactant dysfunction in lung contusion injury in mice.

Authors:  David Machado-Aranda; Zhengdong Wang; Bi Yu; M V Suresh; Robert H Notter; Krishnan Raghavendran
Journal:  Surgery       Date:  2012-07-31       Impact factor: 3.982
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.